Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.42 Consensus Price Target from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $49.91.

Several brokerages recently issued reports on DYN. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Chardan Capital reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada began coverage on Dyne Therapeutics in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective on the stock.

Insider Buying and Selling

In related news, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the completion of the sale, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock valued at $1,443,246 over the last ninety days. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Dyne Therapeutics in the third quarter valued at about $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $36,000. US Bancorp DE increased its stake in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Dyne Therapeutics during the 3rd quarter worth approximately $62,000. Finally, KBC Group NV lifted its stake in Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 2.7 %

NASDAQ DYN opened at $24.76 on Monday. Dyne Therapeutics has a 1-year low of $14.29 and a 1-year high of $47.45. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -6.96 and a beta of 1.16. The stock’s 50 day moving average is $27.78 and its two-hundred day moving average is $34.42.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, analysts predict that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.